ApoA-I Mimetic Peptides Promote Pre-Β HDL Formation in Vivo Causing Remodeling of HDL and Triglyceride Accumulation at Higher Dose
Ester Carballo‐Jane,Zhu Chen,Edward A. O’Neill,Jun Wang,Charlotte Burton,Ching H. Chang,Xun Chen,Suzanne S. Eveland,Betsy Frantz-Wattley,Karen Gagen,Brian K. Hubbard,Marina Ichetovkin,Silvi Luell,Roger Meurer,Xuelei S. Song,Alison M. Strack,Annunziata Langella,Simona Cianetti,Francesca Rech,Elena Capitò,Simone Bufali,Maria Veneziano,Maria Verdirame,Fabio Bonelli,Edith Monteagudo,Antonello Pessi,Raffaele Ingenito,Elisabetta Bianchi
DOI: https://doi.org/10.1016/j.bmc.2010.09.074
IF: 3.461
2010-01-01
Bioorganic & Medicinal Chemistry
Abstract:Reverse cholesterol transport promoted by HDL-apoA-I is an important mechanism of protection against atherosclerosis. We have previously identified apoA-I mimetic peptides by synthesizing analogs of the 22 amino acid apoA-I consensus sequence (apoA-I(cons)) containing non-natural aliphatic amino acids. Here we examined the effect of different aliphatic non-natural amino acids on the structure-activity relationship (SAR) of apoA-I mimetic peptides. These novel apoA-I mimetics, with long hydrocarbon chain (C(5-8)) amino acids incorporated in the amphipathic α helix of the apoA-I(cons), have the following properties: (i) they stimulate in vitro cholesterol efflux from macrophages via ABCA1; (ii) they associate with HDL and cause formation of pre-β HDL particles when incubated with human and mouse plasma; (iii) they associate with HDL and induce pre-β HDL formation in vivo, with a corresponding increase in ABCA1-dependent cholesterol efflux capacity ex vivo; (iv) at high dose they associate with VLDL and induce hypertriglyceridemia in mice. These results suggest our peptide design confers activities that are potentially anti-atherogenic. However a dosing regimen which maximizes their therapeutic properties while minimizing adverse effects needs to be established.